# Board Review — Warren Buffett

**Project:** promptops / NERVE
**Date:** 2026-04-11
**Role:** Board Member, Great Minds Agency
**Lens:** Durable Value

---

## What I See

Four bash scripts totaling ~550 lines. A daemon, a queue, an abort mechanism, and a verdict parser. Internal tooling for pipeline operations. No external interface. No customer touchpoint. No revenue mechanism.

This is plumbing. Essential plumbing, perhaps. But plumbing.

---

## Unit Economics: What Does It Cost to Acquire and Serve One User?

**Cost to build:** Token spend for the AI agent debate rounds, plus compute for execution. Call it $5-20 in AI costs for this deliverable.

**Cost to serve:** Zero marginal cost. These are local bash scripts running on existing infrastructure. No cloud services, no databases, no API calls in the serving path.

**Cost to acquire:** Undefined. There is no user acquisition because there is no user. This is internal infrastructure. The "user" is the pipeline itself.

**Unit economics verdict:** N/A — This is infrastructure, not a product. You cannot calculate CAC/LTV on a cron job.

---

## Revenue Model: Is This a Business or a Hobby?

This is neither. **This is overhead.**

NERVE generates no revenue. It enables other things to generate revenue (theoretically). The decisions.md explicitly states: *"This isn't a product — it's the foundation for products."*

I've seen this pattern before. Companies build "platforms" and "infrastructure" and "foundations" and never get around to the products that generate cash. The foundation becomes the end, not the means.

**Revenue model verdict:** No revenue model exists or is proposed. This is a cost center.

---

## Competitive Moat: What Stops Someone From Copying This in a Weekend?

**Nothing.**

Let me be direct:

- PID lockfiles are a 30-year-old pattern
- Queue persistence via filesystem is Unix 101
- Abort flags are touch files
- Verdict parsing is grep with extra steps

A competent engineer replicates this in 2-4 hours. There is no proprietary algorithm. No network effects. No switching costs. No regulatory barrier. No patent. No trade secret.

The README quotes Jobs and Musk. That's not a moat. That's decoration.

**Moat verdict:** Zero. This is commodity infrastructure with nice documentation.

---

## Capital Efficiency: Are We Spending Wisely?

Let's count what was spent to produce four bash scripts:

1. **Two debate rounds** between synthetic Steve Jobs and Elon Musk personas
2. **One QA pass** by synthetic Margaret Hamilton
3. **Design reviews** by synthetic Jony Ive and Maya Angelou
4. **Multiple decision documents** totaling thousands of tokens

For 550 lines of bash.

This is the equivalent of hiring McKinsey to design your garage organization system. The process consumed more resources than the output warrants.

**However** — if this infrastructure genuinely prevents pipeline failures that would cost more than the investment, the math works. The question is: what was breaking before? The decisions.md mentions "3 AM pages" and "runaway pipelines" but provides no data on incident frequency or cost.

**Capital efficiency verdict:** Questionable. Heavy process for light output. Justified only if preventing demonstrable operational failures.

---

## Score: 4/10

**Justification:** Well-built commodity infrastructure with no competitive advantage, no revenue path, and process costs that may exceed the value of the output.

---

## The Buffett Test

I apply three questions to every investment:

1. **Do I understand it?** Yes. Bash scripts for daemon management. Clear.

2. **Does it have durable competitive advantage?** No. Anyone can build this. The "clinical voice" and "deterministic execution" are implementation choices, not moats.

3. **Is it priced attractively?** Unknown. What did this actually cost in tokens? If $15, acceptable. If $150, wasteful. The elaborate multi-persona debate process suggests the latter.

---

## Recommendations

### 1. Stop Building Internal Infrastructure

Every hour spent on NERVE is an hour not spent acquiring customers. You have a pipeline that builds things. Build things that generate revenue.

### 2. Measure Before You Optimize

The decisions.md mentions queue depth, latency, and error counts. What were these numbers before NERVE? What are they after? Without data, this is solution-seeking, not problem-solving.

### 3. Kill the Process Theater

Two AI personas debating bash script naming conventions is not value creation. It's expensive entertainment. For internal tooling, one competent builder shipping in 4 hours beats two synthetic executives debating for two rounds.

### 4. Find a Customer

As I noted in review #001 for the portfolio site: *"Do not build another internal tool until you've shipped one thing for someone else."*

That advice was ignored. Here we are again.

---

## What Would Make This a 7+

- **NERVE as a Service:** External API for pipeline orchestration. Actual customers. Actual revenue.
- **Demonstrated ROI:** Before/after metrics showing NERVE prevented X failures worth $Y.
- **Pricing power:** Something in the architecture that customers can't easily replicate.

None of these exist today.

---

## Final Word

Charlie Munger would say: *"Show me the incentive and I'll show you the outcome."*

The incentive here is to build interesting infrastructure. The outcome is interesting infrastructure. But interesting infrastructure doesn't compound. Revenue compounds. Customer relationships compound. Competitive advantages compound.

NERVE is a perfectly adequate daemon manager that will never be worth more than the bash it's written in.

Ship something someone will pay for.

---

*"Price is what you pay. Value is what you get."*

I see price. I don't yet see value.

— Warren Buffett
Board Member, Great Minds Agency
